Context Therapeutics (Context Therapeutics) EBIT per Share : $-1.39 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics EBIT per Share?

Context Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.24. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.39.

During the past 3 years, the average EBIT per Share Growth Rate was -84.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Context Therapeutics's EBIT per Share or its related term are showing as below:

CNTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -84 Med: -52.45 Max: -20.9
Current: -84

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Context Therapeutics was -20.90% per year. The lowest was -84.00% per year. And the median was -52.45% per year.

CNTX's 3-Year EBIT Growth Rate is ranked worse than
95.65% of 1309 companies
in the Biotechnology industry
Industry Median: 3.6 vs CNTX: -84.00

Context Therapeutics's EBIT for the three months ended in Mar. 2024 was $-3.82 Mil.

Context Therapeutics EBIT per Share Historical Data

The historical data trend for Context Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics EBIT per Share Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.52

0.72

-3.67

-0.93

-1.57

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-0.42	-0.33	-0.39	-0.43	-0.24

Context Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Context Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.073	/	15.966
=	-1.57

Context Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.824	/	15.966
=	-0.24

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.39

Context Therapeutics (NAS:CNTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Context Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (Context Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Executives

Martin A. Lehr	director, officer: Chief Executive Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary	officer: Chief Financial Officer	110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit	officer: Chief Legal Officer, Corp. Sec	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud	officer: Chief Medical Officer	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey	director	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West	director	C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick	officer: SVP of R&D	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher	officer: Head of CMC and Regulatory	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104